The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Children Respiratory Syncytial Virus Therapeutics Market Research Report 2025
Synopsis
The global Children Respiratory Syncytial Virus Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Children Respiratory Syncytial Virus Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Children Respiratory Syncytial Virus Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Children Respiratory Syncytial Virus Therapeutics include F.Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co.,Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc, ReViral Ltd., Gilead Sciences, Inc. and Medivir AB, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Children Respiratory Syncytial Virus Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Children Respiratory Syncytial Virus Therapeutics.
Report Scope
The Children Respiratory Syncytial Virus Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Children Respiratory Syncytial Virus Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Children Respiratory Syncytial Virus Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F.Hoffmann-La Roche Ltd.
AstraZeneca plc
Merck & Co.,Inc.
AbbVie, Inc.
Valeant Pharmaceuticals International, Inc.
GlaxoSmithKline plc
ReViral Ltd.
Gilead Sciences, Inc.
Medivir AB
Teva Pharmaceuticals Industries Ltd.
Segment by Type
Oral
lnjectable
Others
Segment by Application
Drug Stores and Retail Pharmacies
Hospital Pharmacies
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Children Respiratory Syncytial Virus Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Children Respiratory Syncytial Virus Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Children Respiratory Syncytial Virus Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Children Respiratory Syncytial Virus Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Children Respiratory Syncytial Virus Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Children Respiratory Syncytial Virus Therapeutics include F.Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co.,Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc, ReViral Ltd., Gilead Sciences, Inc. and Medivir AB, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Children Respiratory Syncytial Virus Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Children Respiratory Syncytial Virus Therapeutics.
Report Scope
The Children Respiratory Syncytial Virus Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Children Respiratory Syncytial Virus Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Children Respiratory Syncytial Virus Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F.Hoffmann-La Roche Ltd.
AstraZeneca plc
Merck & Co.,Inc.
AbbVie, Inc.
Valeant Pharmaceuticals International, Inc.
GlaxoSmithKline plc
ReViral Ltd.
Gilead Sciences, Inc.
Medivir AB
Teva Pharmaceuticals Industries Ltd.
Segment by Type
Oral
lnjectable
Others
Segment by Application
Drug Stores and Retail Pharmacies
Hospital Pharmacies
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Children Respiratory Syncytial Virus Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Children Respiratory Syncytial Virus Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Children Respiratory Syncytial Virus Therapeutics Market Overview
1.1 Product Overview and Scope of Children Respiratory Syncytial Virus Therapeutics
1.2 Children Respiratory Syncytial Virus Therapeutics Segment by Type
1.2.1 Global Children Respiratory Syncytial Virus Therapeutics Market Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 lnjectable
1.2.4 Others
1.3 Children Respiratory Syncytial Virus Therapeutics Segment by Application
1.3.1 Global Children Respiratory Syncytial Virus Therapeutics Market Value by Application: (2024-2030)
1.3.2 Drug Stores and Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Others
1.4 Global Children Respiratory Syncytial Virus Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Children Respiratory Syncytial Virus Therapeutics Revenue 2019-2030
1.4.2 Global Children Respiratory Syncytial Virus Therapeutics Sales 2019-2030
1.4.3 Global Children Respiratory Syncytial Virus Therapeutics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Children Respiratory Syncytial Virus Therapeutics Market Competition by Manufacturers
2.1 Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Children Respiratory Syncytial Virus Therapeutics Average Price by Manufacturers (2019-2024)
2.4 Global Children Respiratory Syncytial Virus Therapeutics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Children Respiratory Syncytial Virus Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Children Respiratory Syncytial Virus Therapeutics, Product Type & Application
2.7 Children Respiratory Syncytial Virus Therapeutics Market Competitive Situation and Trends
2.7.1 Children Respiratory Syncytial Virus Therapeutics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Children Respiratory Syncytial Virus Therapeutics Players Market Share by Revenue
2.7.3 Global Children Respiratory Syncytial Virus Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Children Respiratory Syncytial Virus Therapeutics Retrospective Market Scenario by Region
3.1 Global Children Respiratory Syncytial Virus Therapeutics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Children Respiratory Syncytial Virus Therapeutics Global Children Respiratory Syncytial Virus Therapeutics Sales by Region: 2019-2030
3.2.1 Global Children Respiratory Syncytial Virus Therapeutics Sales by Region: 2019-2024
3.2.2 Global Children Respiratory Syncytial Virus Therapeutics Sales by Region: 2025-2030
3.3 Global Children Respiratory Syncytial Virus Therapeutics Global Children Respiratory Syncytial Virus Therapeutics Revenue by Region: 2019-2030
3.3.1 Global Children Respiratory Syncytial Virus Therapeutics Revenue by Region: 2019-2024
3.3.2 Global Children Respiratory Syncytial Virus Therapeutics Revenue by Region: 2025-2030
3.4 North America Children Respiratory Syncytial Virus Therapeutics Market Facts & Figures by Country
3.4.1 North America Children Respiratory Syncytial Virus Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2030)
3.4.3 North America Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Children Respiratory Syncytial Virus Therapeutics Market Facts & Figures by Country
3.5.1 Europe Children Respiratory Syncytial Virus Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2030)
3.5.3 Europe Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Children Respiratory Syncytial Virus Therapeutics Market Facts & Figures by Country
3.6.1 Asia Pacific Children Respiratory Syncytial Virus Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2030)
3.6.3 Asia Pacific Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Children Respiratory Syncytial Virus Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Children Respiratory Syncytial Virus Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2030)
3.7.3 Latin America Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Children Respiratory Syncytial Virus Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Children Respiratory Syncytial Virus Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Children Respiratory Syncytial Virus Therapeutics Sales by Type (2019-2030)
4.1.1 Global Children Respiratory Syncytial Virus Therapeutics Sales by Type (2019-2024)
4.1.2 Global Children Respiratory Syncytial Virus Therapeutics Sales by Type (2025-2030)
4.1.3 Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Type (2019-2030)
4.2 Global Children Respiratory Syncytial Virus Therapeutics Revenue by Type (2019-2030)
4.2.1 Global Children Respiratory Syncytial Virus Therapeutics Revenue by Type (2019-2024)
4.2.2 Global Children Respiratory Syncytial Virus Therapeutics Revenue by Type (2025-2030)
4.2.3 Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Type (2019-2030)
4.3 Global Children Respiratory Syncytial Virus Therapeutics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Children Respiratory Syncytial Virus Therapeutics Sales by Application (2019-2030)
5.1.1 Global Children Respiratory Syncytial Virus Therapeutics Sales by Application (2019-2024)
5.1.2 Global Children Respiratory Syncytial Virus Therapeutics Sales by Application (2025-2030)
5.1.3 Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Application (2019-2030)
5.2 Global Children Respiratory Syncytial Virus Therapeutics Revenue by Application (2019-2030)
5.2.1 Global Children Respiratory Syncytial Virus Therapeutics Revenue by Application (2019-2024)
5.2.2 Global Children Respiratory Syncytial Virus Therapeutics Revenue by Application (2025-2030)
5.2.3 Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Application (2019-2030)
5.3 Global Children Respiratory Syncytial Virus Therapeutics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 F.Hoffmann-La Roche Ltd.
6.1.1 F.Hoffmann-La Roche Ltd. Corporation Information
6.1.2 F.Hoffmann-La Roche Ltd. Description and Business Overview
6.1.3 F.Hoffmann-La Roche Ltd. Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 F.Hoffmann-La Roche Ltd. Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.1.5 F.Hoffmann-La Roche Ltd. Recent Developments/Updates
6.2 AstraZeneca plc
6.2.1 AstraZeneca plc Corporation Information
6.2.2 AstraZeneca plc Description and Business Overview
6.2.3 AstraZeneca plc Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca plc Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.2.5 AstraZeneca plc Recent Developments/Updates
6.3 Merck & Co.,Inc.
6.3.1 Merck & Co.,Inc. Corporation Information
6.3.2 Merck & Co.,Inc. Description and Business Overview
6.3.3 Merck & Co.,Inc. Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck & Co.,Inc. Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.3.5 Merck & Co.,Inc. Recent Developments/Updates
6.4 AbbVie, Inc.
6.4.1 AbbVie, Inc. Corporation Information
6.4.2 AbbVie, Inc. Description and Business Overview
6.4.3 AbbVie, Inc. Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AbbVie, Inc. Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.4.5 AbbVie, Inc. Recent Developments/Updates
6.5 Valeant Pharmaceuticals International, Inc.
6.5.1 Valeant Pharmaceuticals International, Inc. Corporation Information
6.5.2 Valeant Pharmaceuticals International, Inc. Description and Business Overview
6.5.3 Valeant Pharmaceuticals International, Inc. Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Valeant Pharmaceuticals International, Inc. Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.5.5 Valeant Pharmaceuticals International, Inc. Recent Developments/Updates
6.6 GlaxoSmithKline plc
6.6.1 GlaxoSmithKline plc Corporation Information
6.6.2 GlaxoSmithKline plc Description and Business Overview
6.6.3 GlaxoSmithKline plc Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GlaxoSmithKline plc Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.6.5 GlaxoSmithKline plc Recent Developments/Updates
6.7 ReViral Ltd.
6.6.1 ReViral Ltd. Corporation Information
6.6.2 ReViral Ltd. Description and Business Overview
6.6.3 ReViral Ltd. Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 ReViral Ltd. Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.7.5 ReViral Ltd. Recent Developments/Updates
6.8 Gilead Sciences, Inc.
6.8.1 Gilead Sciences, Inc. Corporation Information
6.8.2 Gilead Sciences, Inc. Description and Business Overview
6.8.3 Gilead Sciences, Inc. Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Gilead Sciences, Inc. Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.8.5 Gilead Sciences, Inc. Recent Developments/Updates
6.9 Medivir AB
6.9.1 Medivir AB Corporation Information
6.9.2 Medivir AB Description and Business Overview
6.9.3 Medivir AB Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Medivir AB Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.9.5 Medivir AB Recent Developments/Updates
6.10 Teva Pharmaceuticals Industries Ltd.
6.10.1 Teva Pharmaceuticals Industries Ltd. Corporation Information
6.10.2 Teva Pharmaceuticals Industries Ltd. Description and Business Overview
6.10.3 Teva Pharmaceuticals Industries Ltd. Children Respiratory Syncytial Virus Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Teva Pharmaceuticals Industries Ltd. Children Respiratory Syncytial Virus Therapeutics Product Portfolio
6.10.5 Teva Pharmaceuticals Industries Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Children Respiratory Syncytial Virus Therapeutics Industry Chain Analysis
7.2 Children Respiratory Syncytial Virus Therapeutics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Children Respiratory Syncytial Virus Therapeutics Production Mode & Process
7.4 Children Respiratory Syncytial Virus Therapeutics Sales and Marketing
7.4.1 Children Respiratory Syncytial Virus Therapeutics Sales Channels
7.4.2 Children Respiratory Syncytial Virus Therapeutics Distributors
7.5 Children Respiratory Syncytial Virus Therapeutics Customers
8 Children Respiratory Syncytial Virus Therapeutics Market Dynamics
8.1 Children Respiratory Syncytial Virus Therapeutics Industry Trends
8.2 Children Respiratory Syncytial Virus Therapeutics Market Drivers
8.3 Children Respiratory Syncytial Virus Therapeutics Market Challenges
8.4 Children Respiratory Syncytial Virus Therapeutics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Children Respiratory Syncytial Virus Therapeutics Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Children Respiratory Syncytial Virus Therapeutics Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Children Respiratory Syncytial Virus Therapeutics Market Competitive Situation by Manufacturers in 2023
Table 4. Global Children Respiratory Syncytial Virus Therapeutics Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Children Respiratory Syncytial Virus Therapeutics Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Children Respiratory Syncytial Virus Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Children Respiratory Syncytial Virus Therapeutics Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Children Respiratory Syncytial Virus Therapeutics, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Children Respiratory Syncytial Virus Therapeutics, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Children Respiratory Syncytial Virus Therapeutics, Product Type & Application
Table 12. Global Key Manufacturers of Children Respiratory Syncytial Virus Therapeutics, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Children Respiratory Syncytial Virus Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Children Respiratory Syncytial Virus Therapeutics as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Children Respiratory Syncytial Virus Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Children Respiratory Syncytial Virus Therapeutics Sales by Region (2019-2024) & (K Units)
Table 18. Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Region (2019-2024)
Table 19. Global Children Respiratory Syncytial Virus Therapeutics Sales by Region (2025-2030) & (K Units)
Table 20. Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Region (2025-2030)
Table 21. Global Children Respiratory Syncytial Virus Therapeutics Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Region (2019-2024)
Table 23. Global Children Respiratory Syncytial Virus Therapeutics Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Region (2025-2030)
Table 25. North America Children Respiratory Syncytial Virus Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2024) & (K Units)
Table 27. North America Children Respiratory Syncytial Virus Therapeutics Sales by Country (2025-2030) & (K Units)
Table 28. North America Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Children Respiratory Syncytial Virus Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2024) & (K Units)
Table 32. Europe Children Respiratory Syncytial Virus Therapeutics Sales by Country (2025-2030) & (K Units)
Table 33. Europe Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Children Respiratory Syncytial Virus Therapeutics Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Children Respiratory Syncytial Virus Therapeutics Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Children Respiratory Syncytial Virus Therapeutics Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Children Respiratory Syncytial Virus Therapeutics Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Children Respiratory Syncytial Virus Therapeutics Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Children Respiratory Syncytial Virus Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Children Respiratory Syncytial Virus Therapeutics Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Children Respiratory Syncytial Virus Therapeutics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Children Respiratory Syncytial Virus Therapeutics Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Children Respiratory Syncytial Virus Therapeutics Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Children Respiratory Syncytial Virus Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Children Respiratory Syncytial Virus Therapeutics Sales (K Units) by Type (2019-2024)
Table 51. Global Children Respiratory Syncytial Virus Therapeutics Sales (K Units) by Type (2025-2030)
Table 52. Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Type (2019-2024)
Table 53. Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Type (2025-2030)
Table 54. Global Children Respiratory Syncytial Virus Therapeutics Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Children Respiratory Syncytial Virus Therapeutics Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Type (2019-2024)
Table 57. Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Type (2025-2030)
Table 58. Global Children Respiratory Syncytial Virus Therapeutics Price (US$/Unit) by Type (2019-2024)
Table 59. Global Children Respiratory Syncytial Virus Therapeutics Price (US$/Unit) by Type (2025-2030)
Table 60. Global Children Respiratory Syncytial Virus Therapeutics Sales (K Units) by Application (2019-2024)
Table 61. Global Children Respiratory Syncytial Virus Therapeutics Sales (K Units) by Application (2025-2030)
Table 62. Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Application (2019-2024)
Table 63. Global Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Application (2025-2030)
Table 64. Global Children Respiratory Syncytial Virus Therapeutics Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Children Respiratory Syncytial Virus Therapeutics Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Application (2019-2024)
Table 67. Global Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Application (2025-2030)
Table 68. Global Children Respiratory Syncytial Virus Therapeutics Price (US$/Unit) by Application (2019-2024)
Table 69. Global Children Respiratory Syncytial Virus Therapeutics Price (US$/Unit) by Application (2025-2030)
Table 70. F.Hoffmann-La Roche Ltd. Corporation Information
Table 71. F.Hoffmann-La Roche Ltd. Description and Business Overview
Table 72. F.Hoffmann-La Roche Ltd. Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. F.Hoffmann-La Roche Ltd. Children Respiratory Syncytial Virus Therapeutics Product
Table 74. F.Hoffmann-La Roche Ltd. Recent Developments/Updates
Table 75. AstraZeneca plc Corporation Information
Table 76. AstraZeneca plc Description and Business Overview
Table 77. AstraZeneca plc Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. AstraZeneca plc Children Respiratory Syncytial Virus Therapeutics Product
Table 79. AstraZeneca plc Recent Developments/Updates
Table 80. Merck & Co.,Inc. Corporation Information
Table 81. Merck & Co.,Inc. Description and Business Overview
Table 82. Merck & Co.,Inc. Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Merck & Co.,Inc. Children Respiratory Syncytial Virus Therapeutics Product
Table 84. Merck & Co.,Inc. Recent Developments/Updates
Table 85. AbbVie, Inc. Corporation Information
Table 86. AbbVie, Inc. Description and Business Overview
Table 87. AbbVie, Inc. Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. AbbVie, Inc. Children Respiratory Syncytial Virus Therapeutics Product
Table 89. AbbVie, Inc. Recent Developments/Updates
Table 90. Valeant Pharmaceuticals International, Inc. Corporation Information
Table 91. Valeant Pharmaceuticals International, Inc. Description and Business Overview
Table 92. Valeant Pharmaceuticals International, Inc. Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Valeant Pharmaceuticals International, Inc. Children Respiratory Syncytial Virus Therapeutics Product
Table 94. Valeant Pharmaceuticals International, Inc. Recent Developments/Updates
Table 95. GlaxoSmithKline plc Corporation Information
Table 96. GlaxoSmithKline plc Description and Business Overview
Table 97. GlaxoSmithKline plc Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. GlaxoSmithKline plc Children Respiratory Syncytial Virus Therapeutics Product
Table 99. GlaxoSmithKline plc Recent Developments/Updates
Table 100. ReViral Ltd. Corporation Information
Table 101. ReViral Ltd. Description and Business Overview
Table 102. ReViral Ltd. Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. ReViral Ltd. Children Respiratory Syncytial Virus Therapeutics Product
Table 104. ReViral Ltd. Recent Developments/Updates
Table 105. Gilead Sciences, Inc. Corporation Information
Table 106. Gilead Sciences, Inc. Description and Business Overview
Table 107. Gilead Sciences, Inc. Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Gilead Sciences, Inc. Children Respiratory Syncytial Virus Therapeutics Product
Table 109. Gilead Sciences, Inc. Recent Developments/Updates
Table 110. Medivir AB Corporation Information
Table 111. Medivir AB Description and Business Overview
Table 112. Medivir AB Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Medivir AB Children Respiratory Syncytial Virus Therapeutics Product
Table 114. Medivir AB Recent Developments/Updates
Table 115. Teva Pharmaceuticals Industries Ltd. Corporation Information
Table 116. Teva Pharmaceuticals Industries Ltd. Description and Business Overview
Table 117. Teva Pharmaceuticals Industries Ltd. Children Respiratory Syncytial Virus Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Teva Pharmaceuticals Industries Ltd. Children Respiratory Syncytial Virus Therapeutics Product
Table 119. Teva Pharmaceuticals Industries Ltd. Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Children Respiratory Syncytial Virus Therapeutics Distributors List
Table 123. Children Respiratory Syncytial Virus Therapeutics Customers List
Table 124. Children Respiratory Syncytial Virus Therapeutics Market Trends
Table 125. Children Respiratory Syncytial Virus Therapeutics Market Drivers
Table 126. Children Respiratory Syncytial Virus Therapeutics Market Challenges
Table 127. Children Respiratory Syncytial Virus Therapeutics Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Children Respiratory Syncytial Virus Therapeutics
Figure 2. Global Children Respiratory Syncytial Virus Therapeutics Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Children Respiratory Syncytial Virus Therapeutics Market Share by Type in 2023 & 2030
Figure 4. Oral Product Picture
Figure 5. lnjectable Product Picture
Figure 6. Others Product Picture
Figure 7. Global Children Respiratory Syncytial Virus Therapeutics Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Children Respiratory Syncytial Virus Therapeutics Market Share by Application in 2023 & 2030
Figure 9. Drug Stores and Retail Pharmacies
Figure 10. Hospital Pharmacies
Figure 11. Others
Figure 12. Global Children Respiratory Syncytial Virus Therapeutics Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Children Respiratory Syncytial Virus Therapeutics Market Size (2019-2030) & (US$ Million)
Figure 14. Global Children Respiratory Syncytial Virus Therapeutics Sales (2019-2030) & (K Units)
Figure 15. Global Children Respiratory Syncytial Virus Therapeutics Average Price (US$/Unit) & (2019-2030)
Figure 16. Children Respiratory Syncytial Virus Therapeutics Report Years Considered
Figure 17. Children Respiratory Syncytial Virus Therapeutics Sales Share by Manufacturers in 2023
Figure 18. Global Children Respiratory Syncytial Virus Therapeutics Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Children Respiratory Syncytial Virus Therapeutics Players: Market Share by Revenue in 2023
Figure 20. Children Respiratory Syncytial Virus Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Children Respiratory Syncytial Virus Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Country (2019-2030)
Figure 23. North America Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Country (2019-2030)
Figure 24. United States Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Country (2019-2030)
Figure 27. Europe Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Country (2019-2030)
Figure 28. Germany Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Netherlands Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Region (2019-2030)
Figure 35. China Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. China Taiwan Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Country (2019-2030)
Figure 43. Latin America Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Country (2019-2030)
Figure 44. Mexico Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Children Respiratory Syncytial Virus Therapeutics Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Children Respiratory Syncytial Virus Therapeutics Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Children Respiratory Syncytial Virus Therapeutics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Children Respiratory Syncytial Virus Therapeutics by Type (2019-2030)
Figure 53. Global Revenue Market Share of Children Respiratory Syncytial Virus Therapeutics by Type (2019-2030)
Figure 54. Global Children Respiratory Syncytial Virus Therapeutics Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of Children Respiratory Syncytial Virus Therapeutics by Application (2019-2030)
Figure 56. Global Revenue Market Share of Children Respiratory Syncytial Virus Therapeutics by Application (2019-2030)
Figure 57. Global Children Respiratory Syncytial Virus Therapeutics Price (US$/Unit) by Application (2019-2030)
Figure 58. Children Respiratory Syncytial Virus Therapeutics Value Chain
Figure 59. Children Respiratory Syncytial Virus Therapeutics Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
